Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep 22:8:100256.
doi: 10.1016/j.ajpc.2021.100256. eCollection 2021 Dec.

Aspirin for cardiovascular disease prevention among adults in the United States: Trends, prevalence, and participant characteristics associated with use

Ellen Boakye  1   2 , S M Iftekhar Uddin  3 , Olufunmilayo H Obisesan  4 , Albert D Osei  4 , Omar Dzaye  1 , Garima Sharma  1 , John William McEvoy  1 , Roger Blumenthal  1 , Michael J Blaha  1   2
Affiliations

Aspirin for cardiovascular disease prevention among adults in the United States: Trends, prevalence, and participant characteristics associated with use

Ellen Boakye et al. Am J Prev Cardiol. .

Abstract

Objective: : Aspirin has been widely utilized over several decades for atherosclerotic cardiovascular disease (ASCVD) prevention among adults in the United States. We examined trends in aspirin use among adults aged ≥40 years from 1998 to 2019 and assessed factors associated with its use for primary and secondary ASCVD prevention.

Methods: : Using 1998-2019 Behavioral Risk Factor Surveillance System data, we obtained weighted prevalence of aspirin use among adults aged ≥40 years for each year and examined trends in use over this period. Using multivariable logistic regression and utilizing data from 54,388 respondents aged ≥40 years in the 2019 data, we assessed factors associated with aspirin use for secondary prevention and for primary prevention stratified by the number of traditional ASCVD risk factors reported (hypertension, diabetes mellitus, high cholesterol, overweight/obesity, and cigarette smoking).

Results: : Aspirin use prevalence increased from 29.0%(95%CI, 27.9%-30.2%) in 1998 to 37.5%(36.9%-38.0%) in 2009. However, use has slightly declined over the last decade: 35.6%(34.6%-36.6%) in 2011 to 33.5%(32.5%-34.6%) in 2019. In 2019, among respondents without cardiovascular disease (CVD), 27.5%(26.4%-28.6%) reported primary prevention aspirin use while 69.7%(67.0%-72.2%) of respondents with CVD reported secondary prevention aspirin use. Of concern, 45.6%(43.5%-47.7%) of adults aged ≥70 years without CVD reported primary prevention aspirin use. Additionally, among individuals without any self-reported traditional ASCVD risk factor, males (adjusted odds ratio(aOR):1.60, 95%CI:1.12-2.27), persons aged ≥70 years (aOR:3.22, 95%CI:2.27-4.55), and individuals with healthcare coverage (aOR:2.28, 95%CI:1.17-4.44) had higher odds of primary prevention aspirin use compared to females, persons aged 40-69 years, and individuals without healthcare coverage, respectively. Females were less likely than males to report secondary prevention aspirin use (aOR:0.64, 95%CI:0.50-0.82).

Conclusion: : Aspirin use has slightly declined over the last decade. A significant proportion of adults aged ≥70 years reported primary prevention aspirin use in 2019. Since current guidelines do not recommend primary prevention aspirin use among adults aged ≥70 years, such use should be discouraged.

Keywords: Aspirin; Primary prevention; Secondary prevention; Trends.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Image, graphical abstract
Graphical abstract
Fig. 1
Fig. 1
Trends in aspirin use among adults ≥40 years in the united states, behavioral risk factor surveillance system (1998–2019).
See this image and copyright information in PMC

References

    1. Virani S.S., Alonso A., Aparicio H.J. Heart disease and stroke statistics—2021 update: a report from the American Heart Association. Circulation. 2021;143:254–743. doi: 10.1161/cir.0000000000000950. - DOI - PubMed
    1. Montinari M.R., Minelli S., De Caterina R. The first 3500 years of aspirin history from its roots – a concise summary. Vascul Pharmacol. 2019;113:1–8. doi: 10.1016/j.vph.2018.10.008. - DOI - PubMed
    1. Elwood P.C., Sweetnam P.M. Aspirin and secondary mortality after myocardial infarction. Lancet. 1979;314(8156–8157):1313–1315. doi: 10.1016/S0140-6736(79)92808-3. - DOI - PubMed
    1. Altman R., Carreras L., Diaz R. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J. 1994;308(6921):81–106. - PMC - PubMed
    1. Edney P., Jackson P., Burrell B. Antiplatelet treatment reduces the risk of non-fatal vascular events and, to a lesser extent, vascular death. Br Med J. 1988;296(6618):320–331. doi: 10.1136/bmj.296.6618.320. - DOI